

# Adverse Event Collection Recommendations



## Project Scope

This project team will create a White Paper with recommendations for Adverse Event Collection Instructions, with a focus on Phase 2-4 clinical trials. This project will build upon a paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices.

Project Leads	Emails
Aimee Basile, <i>Otsuka Pharmaceutical</i>	<a href="mailto:Aimee.Basile@otsuka-us.com">Aimee.Basile@otsuka-us.com</a>
Mary Nilsson, <i>Eli Lilly</i>	<a href="mailto:nilsson_mary_e@lilly.com">nilsson_mary_e@lilly.com</a>
Nicola Newton, <i>PHUSE Project Assistant</i>	<a href="mailto:nicky@phuse.global">nicky@phuse.global</a>

Objectives & Deliverables	Timelines
Publish White Paper	Q2 2024

## CURRENT STATUS Q1 2024

- The AE collection white paper went out for public review – comments due 14 February.

Published Deliverables	Date
Blog – Investigator Assessment of Causality – Opportunity for Simplification?	15-Dec-2021
Adverse Event Collection & Treatment Emergent Collection: Version 1.0	27-Aug-2020